BioHarvest Sciences Inc.

BHSC

CA09076J1084

Food Processing

Market Closed - Canadian Securities Exchange Other stock markets 03:46:47 2024-05-03 pm EDT			5-day change	1st Jan Change
0.255 ^CAD	-1.92%		-1.92%	+18.60%

Apr. 30	BioHarvest Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 16	BioHarvest Sciences Inc. Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity	CI

Bioharvest Sciences Inc. Provides Revenue Guidance for the Year 2022 and 2023

December 15, 2022 at 07:41 am EST

Bioharvest Sciences Inc. Provided Revenue Guidance for the Year 2023. For the year, the company is estimating 2023 revenue to be between USD 17 million to USD 20 million, representing a significant growth of at least 3X over 2022. Revenue for 2022 is now estimated to be USD 5.5 million to USD 5.7 million, meeting the guidance range provided by the company in First Quarter of this year.

Latest news about BioHarvest Sciences Inc.

BioHarvest Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
BioHarvest Sciences Inc. Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity	Apr. 16	CI
BioHarvest Sciences Signs First Contracts with Two Industrial Customers to Develop Complex Molecules	Feb. 26	MT
BioHarvest Sciences Inc. Announces Launch of New Contract Development and Manufacturing Organization Business Unit	Feb. 26	CI
BioHarvest Sciences Inc. Signs First Contracts with Two Industrial Customers to Develop Complex Molecules Via Its Newly Launched Botanical Synthesis CDMO Business Unit	Feb. 26	CI
BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding	Dec. 26	CI
Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products	Dec. 13	CI
BioHarvest Sciences Inc. Provides Revenue Guidance for the Fourth Quarter 2023	Nov. 29	CI
Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023	Nov. 29	CI
BioHarvest Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 27	CI
BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding	23-10-18	CI
BioHarvest Sciences Inc. Receives Canadian Product License from Health Canada's Natural and Non-Prescription Health Products Directorate	23-10-10	CI
BioHarvest Sciences Inc. Provides Revenue Guidance for the Third Quarter of 2023	23-08-29	CI
BioHarvest Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
BioHarvest Sciences Up After Reporting Closing of Private Placement of Convertible Notes	23-07-18	MT
BioHarvest Sciences Inc. announced that it has received CAD 4.642076 million in funding	23-07-17	CI
BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in funding	23-07-06	CI
BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board	23-06-06	CI
Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023	23-05-31	CI
BioHarvest Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
BioHarvest Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
BioHarvest Sciences Inc. Auditor Raises 'Going Concern' Doubt	23-04-26	CI
Bioharvest Sciences Inc. Hires Dr. Ilana Belzer as Chief Operating Officer	23-04-19	CI
BioHarvest Sciences Inc. announced that it has received CAD 8 million in funding	23-02-20	CI
BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic Neuritis	23-02-14	CI

Chart BioHarvest Sciences Inc.

Duration

Period

More charts

Company Profile

BioHarvest Sciences Inc. is a Canada-based biotechnology company. The Company offers Botanical Synthesis, its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. The Company is leveraging its Botanical Synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. The Company operates through two segments: Nutraceuticals and Pharmaceuticals. The Company offers a polyphenol/antioxidant superfruit product called VINIA, which is a red grape powder that supplies the benefits of red wine consumption but without the sugar, calories and alcohol found in wine.

Sector

Food Processing

Calendar

2024-05-27 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
BIOHARVEST SCIENCES INC.	+18.60%	107M
ZHEJIANG NHU COMPANY LTD.	+13.21%	8.15B
BELLRING BRANDS, INC.	+3.16%	7.52B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+12.30%	6.65B
THE SIMPLY GOOD FOODS COMPANY	-5.71%	3.73B
BYHEALTH CO., LTD	-6.99%	3.72B
XIAMEN KINGDOMWAY GROUP COMPANY	-4.78%	1.31B
SIRIO PHARMA CO., LTD.	+12.61%	972M
HERBALIFE LTD.	-37.22%	958M
USANA HEALTH SCIENCES, INC.	-15.02%	876M